34229BDA-4BF2-4537-A663-15896F6E269A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 172.634691195795
- age_years
- 14
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.539
- G2M_CHECKPOINT+0.537
- MYC_TARGETS_V1+0.494
- E2F_TARGETS+0.451
- PROTEIN_SECRETION+0.424
- NOTCH_SIGNALING+0.402
- MITOTIC_SPINDLE+0.378
- UV_RESPONSE_DN+0.357
- MTORC1_SIGNALING+0.331
- DNA_REPAIR+0.326
Top 10 suppressed
- KRAS_SIGNALING_DN-0.331
- MYOGENESIS-0.162
- PANCREAS_BETA_CELLS-0.131
- APICAL_SURFACE-0.079
- SPERMATOGENESIS-0.070
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.034
- INTERFERON_ALPHA_RESPONSE-0.010
- ALLOGRAFT_REJECTION+0.014
- P53_PATHWAY+0.033
- COAGULATION+0.046
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.931 |
| 2 | 01169BCB-82ED-4492-9FD0-630CCEA70023 | — | — | 0.922 |
| 3 | 8D30F824-25B9-43DB-BD39-2C9C790509DD | — | — | 0.910 |
| 4 | SRR934827 | — | — | 0.906 |
| 5 | 633064DB-D3ED-4B5F-B48F-6924AD719647 | — | — | 0.901 |
| 6 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.893 |
| 7 | 56C8EE15-BEBA-4919-9E57-FA82E90655D8 | — | — | 0.891 |
| 8 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.890 |
| 9 | F8F6611A-A71A-4847-92B2-15723B9ED0B8 | — | — | 0.889 |
| 10 | A21476BD-0550-4D87-80EA-6E1454E0896D | — | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.539 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.537 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.494 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.451 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.424 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.402 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.378 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.357 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.331 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.326 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.318 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.313 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.306 | Idelalisib | — uncovered |
| APOPTOSIS | 0.276 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.245 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.239 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.237 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.205 | Inavolisib | — uncovered |